The Neuromodulation market size was estimated to be US$ 8.87 billion in 2021 and US$ XX billion in 2023 and is expected to reach US$ 28.32 billion by 2031; it is estimated to record a CAGR of 15.2% in 2023–2031. The increasing incidence of neurological disorders and growing developments in neuromodulation technology are driving factors.  Technological advancements will likely remain key neuromodulation market trends.

Neuromodulation Market Analysis

Neuromodulation devices contain small electrodes on the spinal cord, brain, or peripheral nerves. Neurological disorders such as cerebrovascular diseases, Parkinson's disease, and Alzheimer's disease impact the neurological functioning of the body and hence can be cured with the help of neuromodulation. Furthermore, there are growing developments by medical device companies in neuromodulation and increasing training programs to treat neurological disorders. For instance, in December 2023, a training program on neuromodulation techniques in mental health by the Centre for Advanced Research and Excellence in Neuromodulation for medical professionals was launched at the AIIMS.

Neuromodulation Market Overview

North America is the largest market for neuromodulation. The growth is mainly driven by the incidences of neurological conditions such as Parkinson’s disease, epilepsy, Alzheimer’s disease, and depression, among others. For instance, as per the CDC, the people living with Alzheimer’s disease double up every 5 years of age 65 and by 2060 this number is expected to triple to 14 million people by 2060. Among all ethnic group, as compared to men, women are nearly two times more likely to be affected by Alzheimer's disease. Furthermore, among Americans aged 65 and older, Alzheimer’s remains the fifth-leading cause of death, due to which deaths from stroke, heart disease, and HIV have increased by more than 145% between 2000 and 2019.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Neuromodulation Market: Strategic Insights

Neuromodulation Market

• 
  CAGR (2023 - 2031)

  15.2%
• Market Size 2021
  US$ 8.87 Billion
• Market Size 2031
  US$ 28.32 Billion

Market Dynamics

GROWTH DRIVERS

• Growing Developments in Neuromodulation Technology

FUTURE TRENDS

• Technological Advancements

OPPORTUNITIES

• Rising Demand for Neurostimulation Devices to Treat Chronic Pain

Key Players

• Abbott,
• Boston Scientific Corporation,
• Medtronic,
• NeuroPace, Inc.,
• NeuroSigma, Inc.,
• NEVRO CORP.,
• Synapse Biomedical Inc.,
• Soterix Medical Inc,
• Integer Holdings Corporation,
• Magstim,

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Technology

• External

Application

• Chronic Pain Management
• Failed Back Syndrome
• Epilepsy
• Tremor
• Incontinence
• Depression
• Dystonia
• Gastroparesis
• Parkinson Diseases
• Obsessive-Complusive Disorder
• Migraine

End User

• Hospitals
• Clinics
• Home Healthcare

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Neuromodulation Market Drivers and Opportunities

Growing Developments in Neuromodulation Technology

Neuromodulators alter nerve activity by precisely delivering electrical or pharmaceutical agents at the target site. These are repeatedly used for chronic pain relief and growing technological has increased its applications. For instance, in November 2022, CVRx launched a new neuromodulation device to treat heart failure. This neuromodulation device treats the symptoms of heart failure, a new Barostim NEO2 implantable pulse generator (IPG). This second-generation reduces the size of the IPG by 10% and widens battery life by 20%, thus reducing the device frequency replacements for patients and their providers. Furthermore, in April 2021, Medtronic announced the FDA approval to proceed with an investigational device exemption (IDE) trial to gauge its internally developed implantable tibial neuromodulation (TNM) device, a therapy intended to deliver relief from symptoms of bladder incontinence.

Rising Demand for Neurostimulation Devices to Treat Chronic Pain – An Opportunity

The demand for pain management devices is growing among the elderly and people who have osteoporosis, rheumatoid arthritis, and other such conditions. NCBI research states that in India, almost 61 million people have osteoporosis and out of these, 80% are women. The peak incidence of osteoporosis in India occurs 10–20 years earlier than in Western countries. Such diseases are demanding neurostimulation devices to treat pain.

Furthermore, several startups are designing devices with a prime focus on neurostimulation therapy. During the therapy, these devices deliver electrical stimulation to the spinal cord, dorsal root ganglion, and brain that helps relax muscles and reduce pain. Thus, the advantages of neurostimulation therapy have encouraged the development of enhanced products in the neuromodulation market.

Adoptions of neuromodulation devices have increased significantly across various North American, European, and Asian countries.

Neuromodulation Market Report Segmentation Analysis

Key segments that contributed to the derivation of the neuromodulation market analysis are technology, application, and distribution channels.

• Based on technology, the neuromodulation market is divided into external (non-invasive) neuromodulation and internal neuromodulation. External neuromodulation is further sub-segmented as respiratory electrical stimulation (RES), transcutaneous electrical nerve stimulation (TENS), and transcranial magnetic stimulation (TMS). In addition, the internal neuromodulation segment is also sub-segmented as deep brain stimulation (DBS), sacral nerve stimulation (SNS), gastric electrical stimulation (GES), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS). The internal neuromodulation segment held a larger market share in 2023.
• Based on application, the neuromodulation market is divided into depression, dystonia, chronic pain management, failed back syndrome, Parkinson’s disease, epilepsy, tremor, incontinence, gastroparesis, obsessive-compulsive disorder (OCD), and migraine. The chronic pain management segment held a larger market share in 2023.
• Based on the end user, the neuromodulation market is segmented into hospitals, clinics, and home healthcare. The hospitals segment held a larger market share in 2023.

Neuromodulation Market Share Analysis by Geography

The geographic scope of the Neuromodulation market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the neuromodulation market. The market's growth is attributed to increasing developments in the medical device sector for neuromodulation, rising incidences of neurological disorders among people, and mounting demand for neuromodulation devices for chronic pain management. In addition, the economic burden of treating neurological disorders is significantly growing in the country. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Neuromodulation Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Neuromodulation Market News and Recent Developments

The neuromodulation market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for neuromodulation:

• The U.S. Food and Drug Administration (FDA) approved Abbott's Eterna spinal cord stimulation (SCS) system for treating chronic pain. This device provides an improved experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable SCS systems. (Source: Abbott /Press Release, December 2022)
• GrayMatters Health, a developer of digital self-neuromodulation therapies for mental health care, announced the launch of Prism for posttraumatic stress disorder (PTSD) in the United States. Prism for PTSD is the first self-neuromodulation device to receive U.S. Food & Drug Administration (FDA) clearance as a prescribed adjunct to standard of care (SOC) for PTSD and is accessible at 2 U.S. clinics. (Source: GrayMatters Health, Press Release, January 2024)

Neuromodulation Market Report Coverage and Deliverables

The “Neuromodulation Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles